The Absolute Dosage Illusion: The Difference Between What You Ingest and What You Absorb

A supplement manufacturer can print "500 mg of magnesium" on its label. That is legally accurate. It is biologically misleading.

The question is not how much you swallow. The question is how much of that amount crosses the intestinal wall, reaches the bloodstream, and ultimately enters your cells. That journey, from capsule to mitochondria, is governed by a single factor: the molecular form of the bioactive.

Gastric dissolution: the first barrier, the first selection

Everything begins in the stomach. For a mineral to be absorbable, it must first dissolve in the acidic gastric environment and be released as soluble ions or complexes. This is where molecular forms diverge radically.

Magnesium oxide (MgO) is one of the most magnesium-dense forms, which explains its prevalence in budget supplements. But oxide is a strong base. At normal gastric pH, its solubility is very low. The dissolved, and therefore potentially absorbable, fraction remains small. A randomized double-blind study by Walker et al. confirmed that magnesium citrate led to significantly higher serum magnesium concentrations than oxide, all other factors being equal (PubMed).

Citrate, malate, and glycinate are organic forms. They dissolve more readily in an acidic environment, release magnesium in a controlled manner, and present a significantly more favorable absorption profile.

Intestinal transport: passive or active, the form decides

Once dissolved, minerals and vitamins must cross the intestinal epithelial barrier. Two mechanisms coexist: passive diffusion, where the nutrient naturally moves from a more concentrated area to a less concentrated one, and active transport, which relies on specific carrier proteins to shuttle the nutrient into the cell.

Magnesium oxide releases free Mg²⁺ ions. These ions primarily use the passive route, which has limited efficiency and becomes saturated at relatively low doses. Magnesium diglycinate, by contrast, presents itself as a complex where the mineral is bound to an amino acid (glycine). A portion of this complex is absorbed intact via dipeptide transporters (PEPT1, intestinal gateways designed for small protein fragments), a high-capacity pathway (PubMed). This is precisely the mechanism that explains the advantage of chelated forms (where the mineral is "wrapped" in an amino acid), particularly in individuals with reduced intestinal absorption capacity.

The same principle applies to iron. Ferrous sulfate (FeSO₄), the standard form in many iron supplements, generates free Fe²⁺ ions that trigger local oxidative stress in the intestinal mucosa. The result: nausea, constipation, abdominal pain, and ultimately poor compliance. Iron bisglycinate is a stable chelated complex. It uses the same transport pathways as amino acids, bypasses classic inhibition mechanisms (phytates and polyphenols, plant compounds that trap minerals and reduce their absorption), and demonstrates markedly superior digestive tolerability (PubMed). A clinical trial in infants with iron-deficiency anemia measured bioavailability of 90.9% for iron bisglycinate versus 26.7% for ferrous sulfate (PubMed).

Folate and the MTHFR variant: when form determines conversion

Folic acid is the synthetic form of folate. It is ubiquitous in supplements and fortified foods. But folic acid is not folate. It is a precursor that must be converted into 5-methyltetrahydrofolate (5-MTHF), the biologically active form, by an enzyme called MTHFR (methylenetetrahydrofolate reductase).

Approximately 10 to 15% of the European population carries two identical copies of a variant in the MTHFR gene (known as a homozygous carrier of the C677T or A1298C polymorphism). In these individuals, the enzyme works less efficiently: the conversion capacity from folic acid to 5-MTHF is reduced by 30 to 70%. Folic acid accumulates in its unmetabolized form in the blood, without fulfilling its biological function (PubMed).

5-MTHF (methylfolate) requires no enzymatic conversion. It is directly usable by the body, regardless of genetic status. A randomized controlled trial demonstrated that methylfolate supplementation combined with methylcobalamin produced a 48.3% reduction in homocysteine in homozygous carriers, compared to significantly lower results in heterozygous carriers and placebo groups (PubMed).

Displaying "400 µg of folate (folic acid)" without specifying the form is incomplete information for the third of the population that cannot efficiently convert that folic acid.

Cyanocobalamin and methylcobalamin: same vitamin, different fate

Cyanocobalamin is the least expensive form of vitamin B12 to produce. It is stable, low in reactivity, and constitutes the majority of budget supplements. To become biologically active, it must shed its cyanide radical and be converted into methylcobalamin or adenosylcobalamin, the active coenzyme forms.

This conversion represents an additional metabolic step that the body must perform at the hepatic level. Methylcobalamin, by contrast, is directly usable. It enters the methylation cycle (a fundamental biochemical process that regulates gene expression, detoxification, and neurotransmitter production) without prior transformation. Studies on tissue retention have shown that methylcobalamin is retained longer in tissues, with lower urinary excretion than cyanocobalamin at equivalent doses.

Hepatic first-pass metabolism is another barrier that is often overlooked. Certain molecules, once absorbed by the intestine, pass through the portal circulation (the blood network connecting the gut to the liver) and reach the liver before entering general circulation. The liver can modify, conjugate, or destroy a significant fraction of these molecules. The molecular form partly determines the extent of this effect.

When a well-absorbed nutrient blocks another

Bioavailability does not operate in isolation. Each nutrient enters an ecosystem where intestinal transporters are shared and metabolic pathways interconnected. A perfectly absorbed bioactive can, by its very presence, compromise the assimilation of another.

The most documented case is the zinc-copper antagonism. Both minerals use the same intestinal transporter (MT1). At high zinc intakes, metallothionein (a metal-trapping protein) production in enterocytes (the cells lining the intestinal wall) increases, sequestering dietary copper before it reaches circulation (PubMed). In practice: a perfectly bioavailable zinc supplement, taken in isolation without adjustment, can cause progressive copper depletion. Form is not enough. The administration context and ratios between nutrients matter as much as the molecule itself.

The reverse also exists: certain combinations amplify biological efficacy. Vitamin D3 increases intestinal calcium absorption. But without vitamin K2, that calcium tends to deposit in arterial walls rather than in the bone matrix. K2 activates osteocalcin (a protein that directs calcium toward bones) and matrix Gla protein (a protein that prevents calcium from depositing in arteries) (PubMed). The D3-K2 synergy illustrates a simple principle: an isolated nutrient, even perfectly absorbed, can produce unintended effects if its metabolic partner is absent.

A supplement can display spectacular doses and deliver very little. Another, more modest in its communication, can achieve real biological efficacy through a correctly selected form and well-calibrated nutrient ratios. A recent comparative study on different magnesium forms illustrates this clearly: microencapsulated magnesium maintained sustained plasma elevation over six hours, whereas oxide produced only an early, transient peak (PubMed).

The next frontier in supplementation is not dosage. It is form, interactions, and the understanding of cellular absorption mechanisms that distinguishes a rigorous approach from a marketing strategy.

Frequently asked questions

Why does the dosage on a supplement label not reflect what the body actually absorbs?#[ + ]

The label dosage indicates the quantity ingested, not the quantity absorbed. Between the two, the bioactive must dissolve in the stomach, cross the intestinal barrier, and survive hepatic first-pass metabolism. The molecular form determines the efficiency of each step, with differences reaching a factor of ten or more.

What is the difference between magnesium oxide and magnesium bisglycinate?#[ + ]

Magnesium oxide dissolves poorly in gastric acid and releases free Mg2+ ions that use a passive absorption pathway with limited capacity. Bisglycinate is a chelated complex that can be absorbed intact via dipeptide transporters (PEPT1), a high-capacity pathway. Clinical studies show at least twice the tissue absorption for organic forms compared to oxide.

What is the MTHFR variant and why does it affect folate absorption?#[ + ]

Approximately 10 to 15% of the European population carries two copies of an MTHFR gene variant that reduces the capacity to convert folic acid into its active form (5-MTHF) by 30 to 70%. For these individuals, folic acid accumulates in its unmetabolized form without fulfilling its biological function. Methylfolate (5-MTHF) bypasses this issue as it is directly usable without enzymatic conversion.

Can a supplement prevent the absorption of another nutrient?#[ + ]

Yes. The most documented example is zinc-copper antagonism: at high doses, zinc stimulates metallothionein production in intestinal cells, which traps copper before it reaches circulation. Conversely, some combinations are synergistic: vitamin D3 increases calcium absorption, and vitamin K2 directs that calcium toward bones rather than arterial walls.

Why does increasing the dose of a poorly absorbable supplement not solve the problem?#[ + ]

If only 4 to 10% of a poorly bioavailable form reaches circulation, increasing the raw dose does not fundamentally compensate for the absorption deficit. Excess free ions in the colon can cause digestive discomfort and interfere with the assimilation of other nutrients. It is the molecular form, not the quantity, that determines real biological efficacy.

---

References

1. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res. 2003;16(3):183-91 (PubMed).
2. Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN J Parenter Enteral Nutr. 1994;18(5):430-5 (PubMed).
3. Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74(6):435-43 (PubMed).
4. Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17(5):381-4 (PubMed).
5. Pokushalov E, Ponomarenko A, Bayramova S, et al. Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin Supplementation on Homocysteine and LDL-C in Patients with MTHFR, MTR, and MTRR Polymorphisms. Nutrients. 2024;16(11):1550 (PubMed).
6. Lizer MH, Bogdan RL, Kidd RS. Comparison of the frequency of the MTHFR C677T polymorphism in depressed versus nondepressed patients. J Psychiatr Pract. 2011;17(6):404-9 (PubMed).
7. Pajuelo D, Meissner JM, Negra T, Connolly A, Mullor JL. Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium Versus Other Magnesium Sources. Nutrients. 2024;16(24):4367 (PubMed).
8. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am J Clin Nutr. 1995;61(3 Suppl):621S-624S (PubMed).
9. van Ballegooijen AJ, Pilz S, Tomaschitz A, Grübler MR, Verheyen N. The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review. Int J Endocrinol. 2017;2017:7454376 (PubMed).